IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2012-02, Vol.119 (8), p.1901-1903
Main Authors: Cairns, Rob A., Iqbal, Javeed, Lemonnier, François, Kucuk, Can, de Leval, Laurence, Jais, Jean-Philippe, Parrens, Marie, Martin, Antoine, Xerri, Luc, Brousset, Pierre, Chan, Li Chong, Chan, Wing-Chung, Gaulard, Philippe, Mak, Tak W.
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Brief Report
Female
Gene Frequency
Genotype
Hematologic and hematopoietic diseases
Humans
Immunoblastic Lymphadenopathy - enzymology
Immunoblastic Lymphadenopathy - genetics
Immunoblastic Lymphadenopathy - pathology
Isocitrate Dehydrogenase - genetics
Kaplan-Meier Estimate
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoid Neoplasia
Lymphoma, T-Cell - enzymology
Lymphoma, T-Cell - genetics
Lymphoma, T-Cell - pathology
Lymphoma, T-Cell, Peripheral - enzymology
Lymphoma, T-Cell, Peripheral - genetics
Lymphoma, T-Cell, Peripheral - pathology
Male
Medical sciences
Mutation
Mutation Rate
Prognosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2011-11-391748